








• To evaluate adherence to an organization’s 
procedure for Tardive Dyskinesia (TD) 
• Data from the electronic medical record 
(EMR) was analyzed to determine the 
number of times clinicians completed the 
electronic Abnormal Involuntary 
Movement Scale (AIMS)
Tardive Dyskinesia:
• Newer antipsychotic medications from 
the 80s up to recent years significantly 
decreased tardive dyskinesia.
• TD affects an estimated 500,000 people 
in the U.S., 60-70 % of all cases are mild 
• Approximately 30 % are moderate to 
extreme and of these more than 40 % 
have extreme anxiety related to their 
symptoms. 
• Approximately 3 % of cases are severe 
• Screening using AIMS can reduce these 
statistic.1 
• VMAT2 drugs treat TD
Antipsychotic Medication Benefit:
• Provide a better  quality of a life  for 
patient with severe mental illnesses
• Provide relief of symptoms of anxiety, 
depression, irritability, sleep difficulty
Antipsychotic Medication Risk:
• Cause metabolic  diseases such as 
diabetes and heart disease
• Cause long term movement disorders
AIMS
• A screening instrument designed to detect
TD with a Cronbach alpha score of  r-0.97
• Evidence-based practice recommends 
annual AIMS screening for all patients 
taking antipsychotics
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• Inclusion criteria all patient/provider 
encounters for clients who were taking 
antipsychotic medications between 
August 19, 2020 and November 26, 
2020 
• De-identified data included at least one 
of the top five most frequently 
prescribed antipsychotic medications; 
• Data included provider type, practice 
settings, encounter date, and whether an 
EMR AIMS assessment was completed. 







Visits Percent Percent per visits
MD 16 765 781 14.8 1.6
DNP 50 364 414 46.3 8.9
PA 42 924 966 38.9 3,3
unknown 0 6 6 0 0
Total 108 2059 2169 100
Discussion
2167 patients treated with antipsychotic agents 
in an outpatient behavioral health clinic. 
5% of  2167 encounters resulted in AIMS
Provider-types:
• MD=Psychiatrists 
• PMHNP = psychiatric and mental health 
nurse practitioner
• PA=Physician’s assistants 
( 4 MDs, 1 PMHNP, and 6 PAs) 
Of the 2169  encounters
• 781were with MDs
• 966 with a PA 
• 414 with the NP (19 %), 12.1 % resulted in 





AIMS not completed Total
aripiprazole 27 591 618
olanzapine 23 402 425
risperidone 31 433 464
quetiapine 26 384 410
clozapine 1 249 250
Total 108 2059 2167
The data did not reflect any of the AIMS assessment 
forms that were manually completed.
Recommendations: 
• Continuous evaluation of adherence to 
clinical practice recommendations
• Give incentives for increased use of the 
electronic AIMS form
• Generate quarterly reports from the 
electronic health record to show 
percentage AIMS completed 
electronically
Sustainability and recommendations: 
• Develop a system to alert the clinician to 
complete monitoring assessments
• Remove paper AIMS forms from clinical 
setting
• Provide AIMS education module
• Extend AIMS completion to counselors
Future Needs: 
• Conclusive studies showing benefit of 
screening
• Improved scoring and
• Consistent and ongoing training for all 
staff to create a more collaborative 
approach to medication management





Total visits without AIMS completed 2059 95
Number of AIMS completed 108 5
Total 2167 100
Five of the most used antipsychotic medications 
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